0001209191-23-002054.txt : 20230105 0001209191-23-002054.hdr.sgml : 20230105 20230105182111 ACCESSION NUMBER: 0001209191-23-002054 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHERWIN STEPHEN A CENTRAL INDEX KEY: 0001079462 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 23512864 MAIL ADDRESS: STREET 1: C/O CELL GENESYS, INC. STREET 2: 500 FORBES BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-03 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001079462 SHERWIN STEPHEN A 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 0 0 0 Common Stock 2023-01-03 4 M 0 15000 12.71 A 40055 D Common Stock 2023-01-03 4 S 0 15000 118.8651 D 25055 D Common Stock 2023-01-03 4 M 0 15000 12.98 A 40055 D Common Stock 2023-01-03 4 S 0 15000 118.8501 D 25055 D Non-Qualified Stock Option 12.71 2023-01-03 4 M 0 15000 12.71 D 2023-05-23 Common Stock 15000 0 D Non-Qualified Stock Option 12.98 2023-01-03 4 M 0 15000 12.98 D 2024-05-22 Common Stock 15000 0 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $117.75 to $119.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted May 23, 2013 and vested monthly over one year. Option granted May 22, 2014 and vested monthly over one year. /s/ Darin Lippoldt, Attorney-in-Fact 2023-01-05